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Abstract
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in the hexosamine biosynthetic path-
way which yields precursors required for protein and lipid glycosylation. Mutations in GFPT1 and other genes downstream of
this pathway cause congenital myasthenic syndrome (CMS) characterized by fatigable muscle weakness owing to impaired
neurotransmission. The precise pathomechanisms at the neuromuscular junction (NMJ) owing to a deficiency in GFPT1 is yet
to be discovered. One of the challenges we face is the viability of Gfpt1/ knockout mice. In this study, we use Cre/LoxP tech-
nology to generate a muscle-specific GFPT1 knockout mouse model, Gfpt1tm1d/tm1d, characteristic of the human CMS pheno-
type. Our data suggest a critical role for muscle derived GFPT1 in the development of the NMJ, neurotransmission, skeletal
muscle integrity and highlight that a deficiency in skeletal muscle alone is sufficient to cause morphological postsynaptic
NMJ changes that are accompanied by presynaptic alterations despite the conservation of neuronal GFPT1 expression. In ad-
dition to the conventional morphological NMJ changes and fatigable muscle weakness, Gfpt1tm1d/tm1d mice display a progres-
sive myopathic phenotype with the presence of tubular aggregates in muscle, characteristic of the GFPT1-CMS phenotype.
We further identify an upregulation of skeletal muscle proteins glypican-1, farnesyltransferase/geranylgeranyltransferase
type-1 subunit a and muscle-specific kinase, which are known to be involved in the differentiation and maintenance of the
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NMJ. The Gfpt1tm1d/tm1d model allows for further investigation of pathophysiological consequences on genes and pathways
downstream of GFPT1 likely to involve misglycosylation or hypoglycosylation of NMJs and muscle targets.
Introduction
Congenital myasthenic syndromes (CMS) are a heterogeneous
group of inherited disorders of neurotransmission that are com-
monly categorized according to the pathophysiological involve-
ment in the presynaptic compartment, synaptic cleft and the
postsynaptic basal lamina of the neuromuscular junction (NMJ).
More recently, mutations in genes encoding ubiquitously
expressed enzymes involved in glycosylation have also been
implicated in CMS (5 out of 29 CMS causing genes) (1–9).
Recessive mutations have been identified in the GFPT1 gene
that encodes glutamine-fructose-6-phosphate transaminase
1 (GFPT1) (7). GFPT1 is a ubiquitous protein that catalyses the
conversion of fructose-6-phosphate to glucosamine-6-phosphate
and glutamate via a transamidase reaction. This is the rate-
limiting step in the hexosamine biosynthetic pathway which
yields precursors required for N- and O-linked glycosylation of
proteins (10). Splicing of GFPT1 gives rise to two variants, a ubiq-
uitous GFPT1 isoform and a long muscle-specific isoform,
GFPT1-L, expressed predominantly in skeletal muscle and the
heart (11). Missense mutations in GFPT1 have been found out-
side of the muscle-specific exon, yet impaired function seems
to be restricted to the muscle and NMJ.
Patients with mutations in GFPT1 demonstrate a progressive
limb-girdle pattern of weakness, tubular aggregates in skeletal
muscle, an unusual sparing of the ocular and bulbar muscles,
and an improvement in symptoms in response to cholinester-
ase inhibitors (2,7,8). Some patients also display a decremental
response to electromyography (EMG) (2,12) and repetitive nerve
stimulation (7–9), and endplates in patient biopsies display sim-
plification of the postsynaptic membrane with fewer and poorly
developed junctional folds (2,8,9,12). Until now there has only
been one report of a human mutation that disrupts the GFPT1-L
isoform resulting in the absence of glycosylated proteins. A pa-
tient biopsy of the anconeus muscle showed abnormal variation
of fibre size, sparse regenerating and necrotic fibres, vacuolated
fibres, endomysial fibrosis and densely packed membranous tu-
bular aggregates (2).
The precise mechanism whereby the NMJ is affected by
defects in glycosylation is not clear. One hypothesis is that
mutations in glycosylation enzymes impair the glycosylation
of proteins involved in the formation and maintenance of the
NMJ and neurotransmission. Here, we report the first CMS
mouse model depicting defective glycosylation. By generating
a muscle-specific GFPT1 deficient mouse model we established
a good phenocopy of the human disorder enabling deeper func-
tional and biochemical studies of the underlying pathology
which leads to the GFPT1-CMS phenotype.
Results
Generation of the GFPT1 muscle-specific knockout
mouse
The basic targeting strategy used in this study has been de-
scribed previously (13). The initial breeding and genotyping
steps required for this study were carried out in-house
(Supplementary Material, Resources S1–S3). To generate a con-
ditional Gfpt1 knockout allele, homozygous mice harbouring
two loxP sites flanking exon 7 of the Gfpt1 gene (Gfpt1tm1c/tm1c)
were bred with mice harbouring the Ckm-Cre transgene
[B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J]. These mice express Cre
recombinase under the control of the Ckm promoter (14).
Homozygous mice with this genotype will be referred to as
Gfpt1tm1d/tm1d. Cre-mediated recombination results in the dele-
tion of Gfpt1 in skeletal and cardiac muscle only (Fig. 1A).
To confirm the spatial and temporal expression of Cre recombi-
nase we used the lacZ reporter mouse line ROSA26R-lacZ that
demonstrates the activity of the Ckm promoter. Our findings
confirmed Ckm-Cre expression in skeletal and cardiac muscle
only (data not shown). Mice homozygous for Gfpt1tm1c/tm1c were
used as controls. Cre-mediated gene alteration in muscle of
Gfpt1 mutant mice was confirmed by genomic polymerase chain
reaction (PCR). Primers were designed to detect the deletion of
Exon 7. PCR on genomic DNA extracted from muscle and non-
muscle tissues from Gfpt1tm1c/tm1c mice produce fragments of
500 bp. DNA amplified from Gfpt1tm1d/tm1d mice produce frag-
ments of 500 bp in non-muscle tissues and a truncated band
of 290 bp in skeletal and cardiac muscle in the presence of
Cre (450 bp). All targeted alleles produce fragments of 170 bp
(Fig. 1B). The expression of GFPT1 in tissues was examined by
western blotting using a polyclonal antibody against GFPT1.
GFPT1 (79 kDa) is expressed in muscle and non-muscle tissues
in control mice. Results confirmed the absence of GFPT1 in skel-
etal and cardiac muscle from Gfpt1tm1d/tm1d mice, whilst main-
taining expression in the brain and kidney. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (38 kDa) was used as a
loading control (Fig. 1C).
Gfpt1tm1d/tm1d mice demonstrate signs of muscle
weakness and fatigue
Gfpt1tm1d/tm1d mice do not exhibit gross phenotypical defects
when compared with age-matched control mice. Although the
general trend shows that Gfpt1tm1d/tm1d mice are slightly smaller
when compared with control mice, no significant differences in
body weight were observed between control and Gfpt1tm1d/tm1d
mice over the course of development (Fig. 2A).
To assess any changes in motor function we performed the
inverted screen test assay over a period of 6 months. Control
mice up to the age of 18 weeks demonstrate the ability to hold
on for the maximum set threshold of 10 min. There was a small
reduction in the latency to fall in older mice that can be
accounted for by an increase in body weight. Gfpt1tm1d/tm1d mice
demonstrate poor motor performance as early as 6 weeks old
onwards, shown by a reduction in the latency to fall from the
grid compared with controls (latency decrease: 8 weeks old,
62%; 12 weeks old, 69%; 16 weeks old, 66%; 20 weeks old, 64%;
24 weeks old, 63%; Fig. 2B). The deficit in motor performance is
not progressive over time. We further demonstrate there is
no change in body weight and hang time between control
mice (Cre negative) and mice carrying the Cre transgene
(Supplementary Material, Resource S4). To confirm the presence
of muscle weakness in Gfpt1tm1d/tm1d mice, we studied the ability
of tibialis anterior (TA) muscles from 3 months old control and
Gfpt1tm1d/tm1d mice to evoke tetanic contractions in response to
stimulation of the sciatic nerve in situ. Analysis of specific force
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[force normalized to cross-sectional area (CSA) of muscle]
revealed no significant differences in muscle strength between
control and Gfpt1tm1d/tm1d mouse muscle (Supplementary
Material, Resource S5). We assessed muscle fatigue over a total
of 100 tetanic nerve stimulations at 120 Hz (the frequency that
resulted in Po). Muscle fatigue was observed in both control and
Gfpt1tm1d/tm1d mice (Fig. 2C). After 100 stimulations, control mice
demonstrated a 26.1% reduction in force produced compared
with baseline, whereas Gfpt1tm1d/tm1d mice showed a 64.7% defi-
cit, exhibiting a more pronounced degree of fatigue. A progres-
sive decrease in force produced in Gfpt1tm1d/tm1d mice is evident
from 80 stimulations (80, 42.9%; 90, 47.7%; 100, 64.7%), whereas
a significant reduction of force in control mice is only evident
following 100 stimulations compared with baseline. A compari-
son of fatigability between control and Gfpt1tm1d/tm1d mice
showed that mutant mice exhibit a significant and progressive
reduction in force produced after 80 (20.8%), 90 (26.4%) and 100
(38.7%) stimulations (Fig. 2D). Our data demonstrate that whilst
deletion of GFPT1 does not have a pronounced effect on TA
muscle strength, the muscle is more susceptible to fatigue.
Contractile properties of Gfpt1tm1d/tm1d diaphragm
muscles
We assessed the contractile properties of diaphragm muscles
from Gfpt1tm1d/tm1d mice using an in vitro test apparatus. We
examined the ability of muscle to contract following a train of
tetanic stimulations. Both control and Gfpt1tm1d/tm1d muscles
maintained tetanic contractions with stimulation frequencies
ranging from 30 to 150 Hz. However, Gfpt1tm1d/tm1d muscles de-
velop less force than control ones (Fig. 2E). Quantitative analysis
revealed that the maximal isometric tetanic force was signifi-
cantly reduced compared with controls (150 Hz, 35.3%).
We tested for fatigue using a series of 100 tetanic nerve
stimulations at 150 Hz (the frequency resulting in Po). We did
not observe signs of fatigue in control diaphragms, but we see a
progressive reduction in force between 50 and 100 stimulations
in Gfpt1tm1d/tm1d diaphragms (Fig. 2F) (50, 5.6%; 60, 16.8%; 70
19.4%; 80, 20.9%; 90, 23.5%; 100, 29.8%). We compared the reduc-
tion in force produced between control and Gfpt1tm1d/tm1d mice
expressed as percentage fatigability. Since we do not observe a
deficit in force in control mice, Gfpt1tm1d/tm1d mice produced sig-
nificantly less force from 50 to 100 stimulations compared with
controls (50, 5.6%; 60, 16.8%; 70, 19.4%; 80, 20.9%; 90, 23.5%; 100,
29.8; Fig. 2G).
Histological changes in skeletal muscle from
Gfpt1tm1d/tm1d mice
Haematoxylin and eosin staining on TA, intercostal, soleus, ex-
tensor digitorum longus (EDL) and diaphragm muscles demon-
strate myopathic changes in Gfpt1tm1d/tm1d mouse (Fig. 3A).
Whilst control mouse muscle fibres maintain their characteris-
tic polygonal shape and peripherally located nuclei, muscles
from Gfpt1tm1d/tm1d mice exhibit occasional rounded myofibres
(asterix), a small number of fibres with internal nuclei (black
arrows), necrotic fibres (white arrow head) and the presence of
atrophic and hypertrophic myofibres, some of which exhibit
splitting. Gfpt1tm1d/tm1d mouse muscle also presented with tubu-
lar aggregates in some myofibres in all muscles examined (black
arrow head), together with the replacement of myofibres with
adipose tissue (white arrows), predominantly found in the dia-
phragm muscle. Quantitative analysis of the CSA of muscle
fibres showed higher variability in Gfpt1tm1d/tm1d mouse muscle
when compared with control mouse muscle (Fig. 3B).
Differences in fibre size between control and Gfpt1tm1d/tm1d
mouse muscle are greatest in the EDL (61%), followed by the so-
leus (56%), intercostal (29%) and TA (26%) muscle, as shown by
Figure 1. Generation of muscle-specific Gfpt1 knockout mice. (A) Schematic demonstrating the genomic region of the Gfpt1 gene where Exon 7 is floxed by loxP sites.
Conversion of the Gfpt1tm1c allele to the Gfpt1tm1d allele in skeletal and cardiac muscle of Gfpt1 mutant mice carrying a Cre transgene under the control of the Ckm pro-
moter. (B) PCR demonstrating recombination events that take place in muscle and non-muscle tissues of Gfpt1tm1d/tm1d mice. (C) Protein lysates from brain, kidney, skel-
etal muscles and the heart of control and mutant mice were analysed by western blotting against a GFPT1 antibody. An antibody against GAPDH was used as a loading
control (n¼ 6).
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the percentage difference of the interquartile range. Median
CSA measurements are indicative of the proportion of fibres
that tend to be either smaller or larger when comparing control
and mutant muscles. The intercostal and soleus muscles ex-
hibit a shift towards smaller fibres (29% and 26%, respectively),
the EDL exhibits a shift towards larger fibres (18%) and the TA
fibres remain unchanged in Gfpt1tm1d/tm1d mice. No differences
were observed in the proportion of fibre types in the soleus
(Fig. 4A and B) or TA (Fig. 4C and D) muscles between control
and mutant mice. Further analyses revealed no significant tubu-
lar aggregate fibre-type-specific predominance in the soleus and
TA muscles (Supplementary Material, Resource S6). No patho-
logical changes were observed in cardiac muscle from Gfpt1tm1d/
tm1d mice compared with controls (data not shown).
Gfpt1tm1d/tm1d mice exhibit presynaptic and postsynaptic
remodelling
We analysed the pre- and post-synaptic molecular structure of
NMJs in TA, intercostal, soleus and EDL muscles from 3 months
old mice. Whole-mount muscles were stained with a-bungaro-
toxin to label acetylcholine receptor (AChR) clusters, and with
antibodies against neurofilament and synaptophysin to label axo-
nal branches and nerve terminals, respectively. In control mice,
axonal branches project normally and innervate the well-defined
‘pretzel’-like AChR cluster. AChR clusters from Gfpt1tm1d/tm1d
mouse muscle do not maintain this characteristic shape, but in-
stead appear smaller and fragmented when compared with
AChRs from control mice (blue arrows). Gfpt1tm1d/tm1d mice also ex-
hibit presynaptic changes including the appearance of discontinu-
ous and disorganized axonal projections (white arrows).
Nevertheless, axons can project normally to endplates and do not
show any signs of overshooting, retractions or axonal sprouting
(magenta arrows) (Fig. 5A). Synaptophysin labelling shows frag-
mented nerve terminals in Gfpt1tm1d/tm1d mice that align with exist-
ing AChR cluster fragments to form synaptic contacts (magenta
arrows) (Fig. 5B). Quantitative analysis revealed a reduction
in AChR cluster area, which was greatest in the TA (45%), followed
by the EDL (33%), soleus (28%) and intercostal (27%) muscles
(Fig. 5C). The mean number of AChR fragments was greater in
muscles from Gfpt1tm1d/tm1d mice than in controls (control versus
Gfpt1tm1d/tm1d; TA: 1.2 versus 3.2, intercostal: 1.4 versus 2.3, soleus
1.1 versus 2.9, EDL: 1.3 versus 2.8) (Fig. 5D). Statistical analysis
revealed the greatest degree of fragmentation in the soleus, fol-
lowed by the EDL, intercostal and TA muscles. The nerve terminals
also exhibit some degree of remodelling in comparison to controls.
To gain an enhanced understanding of the NMJ phenotype,
we used electron microscopy to examine endplates at the ultra-
structural level in intercostal muscles from 3 months old control
(Fig. 6A) and mutant mice (Fig. 6B–H). NMJs in Gfpt1tm1d/tm1d mice
displayed fewer numbers of junctional folds per terminal (red
arrows) (control mean 6SEM: 13.1461.23 versus Gfpt1tm1d/tm1d:
8.7161.70) (Fig. 6B–D; Supplementary Material, Resource S7) on
Figure 2. A comparison of body weight and muscle strength between control and Gfpt1tm1d/tm1d mice. (A) Growth curves demonstrating changes in body weight over a 6
months period (n¼8). (B) Quantitative analysis of latency to fall from a wire grid at various time points up to the age of 6 months (n¼8). Gfpt1tm1d/tm1d mice perform
worse than control mice at all time points (P<0.01). (C) Quantitative analysis of force generated by the TA muscle after every 10 stimulations of the CPN in 3 months
old control and Gfpt1tm1d/tm1d mice (n¼5). Data are expressed as a percentage of baseline force. (D) Quantification of fatigability of the TA muscle after 80, 90 and 100
stimulations of the CPN in 3 months old control and Gfpt1tm1d/tm1d mice (n¼5). Data are expressed as the percentage decrease of baseline force. (E) Isometric tetanic
maximal force in diaphragm muscle from control and Gfpt1tm1d/tm1d mice (n¼4). (F) Quantitative analysis of force generated by the diaphragm muscle after every 10
stimulations in 3 months old control and Gfpt1tm1d/tm1d mice (n¼4). Data are expressed as a percentage of baseline force. (G) Quantification of the fatigability of the dia-
phragm muscle between 50 and 100 stimulations in 3 months old control and Gfpt1tm1d/tm1d mice. Data are expressed as a percentage reduction in force. Data are
mean6SEM. NC, no change; *P<0.05, **P<0.01, ***P<0.001.
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the postsynaptic membrane and an abundant accumulation of
tubular aggregates beneath the sarcolemma in mutant mice
(Fig. 6E). We also see the presence of accumulated subsarcolem-
mal vesicular structures that resemble enlarged caveolae with
impaired sarcolemmal fusion (white arrows) (Fig. 6F–H), and pro-
liferated and/or widened sarcoplasmic reticulum and Golgi struc-
tures as well as deposits of dense filamentous-like material (blue
arrowhead), most likely corresponding to aggregated protein
(Fig. 6G and H). In small pre-terminal intramuscular nerve fas-
cicles from Gfpt1tm1d/tm1d mice, we observed highly irregular con-
voluted myelin sheaths surrounding some axons, associated
with a mean reduction in the diameter of myelin sheaths when
compared with controls (control: 0.526 0.03 mm; Gfpt1tm1d/tm1d:
0.3260.01 mm) (Supplementary Material, Resource S7). Further
analysis revealed that the number of mitochondria per nerve ter-
minal remains unaffected (data not shown). Collectively, our
data indicate the presence of both pre- and postsynaptic altera-
tions of the NMJ and muscle in Gfpt1tm1d/tm1d mice.
Effects of GFPT1 deficiency on caveolin-3
Our electron microscopy data showing the presence of ectopic
subsarcolemmal caveolae-like vesicular structures indicative
of ER-Golgi-stress prompted further investigation into the sub-
cellular distribution and prevalence of caveolin-3 in muscles.
Non-sarcolemmal caveolin-3 positive puncta were observed in
both control and Gfpt1tm1d/tm1d mouse muscle (Fig. 7A), with no
significant differences in the percentage of myofibres showing
Figure 3. Characteristics and myopathic changes in muscle from Gfpt1tm1d/tm1d mice. (A) Representative TA, intercostal, soleus, EDL and diaphragm muscles stained
with haematoxylin and eosin from control and Gfpt1tm1d/tm1d mice. Rounded myofibres (asterix), centrally located nuclei in myofibres (black arrows), tubular aggregates
(black arrow head), necrotic fibres (white arrow head), adipose tissue (white arrows). Hypertrophic and atrophic myofibres are also present. (B) Quantitative analyses
demonstrating the distribution of myofibre size according to CSA. Data are median, 25th percentile, 75th percentile, minimum and maximum values (including out-
liers). **P<0.01; ***P<0.001; ns, not significant (Mann–Whitney U test) (n¼ 4).
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caveolin-3 immunoreactivity in the soleus and TA muscles
from Gfpt1tm1d/tm1d mice compared with controls (Fig. 7B and C).
Quantitative analysis of immunofluorescent cytoplasmic punc-
tate staining corresponding to caveolin-3 revealed significantly
larger puncta in Gfpt1tm1d/tm1d soleus and TA muscles compared
with controls (Fig. 7D and E).
Stability of AChR remains unaffected in Gfpt1tm1d/tm1d
mice
To establish whether the stability of AChRs is compromised in
Gfpt1tm1d/tm1d mice, we assessed the turnover rate of AChRs in the
TA muscle of 3 months old control and mutant mice over a 10-day
period. To avoid muscle paralysis, a non-saturating 25 pmol dose
of a-bungarotoxin was used for labelling ‘old’ and ‘new’ receptors
labelled green and red, respectively. Fluorescence signals were
monitored using confocal microscopy. Quantitative assessment of
relative pixel intensities using automated image analysis demon-
strates no significant difference between Gfpt1tm1d/tm1d and control
mice (Supplementary Material, Resource S8).
Effects of GFPT1 deficiency on the intercostal muscle
proteome
Proteomics is a powerful tool for the unbiased investigation of
pathophysiological processes in neuromuscular disorders (15).
Here, we compared intercostal muscles from 3 months old con-
trol and Gfpt1tm1d/tm1d mice using quantitative mass spectrome-
try (label-free proteomic approach). We found that 2.8% of the
quantified proteins (43 out of 1517) were differentially expressed
upon GFPT1 deficiency in intercostal muscles. Thirty-nine of
these proteins were upregulated (29 identified with a minimum
of 2 unique peptides and 10 with just 1 unique peptide) and
4 downregulated (all identified with 1 unique peptide). Five out
of the 39 upregulated proteins and 1 out of the 4 downregulated
proteins harbour N-glycosylation (N-GlcNAc) sites. One out of
the four downregulated proteins harbour O-glycosylation
(O-GlcNAc) sites (Supplementary Material, Resource S9). Most of
the affected proteins are localized in the ER-Golgi network,
plasma membrane, cytoplasm, nucleus and mitochondria
(Supplementary Material, Resources S10 and S11). An overview
of the regulated proteins and proposed functions is given in
(Supplementary Material, Resource S12). Proteins of interest in-
clude glypican-1, muscle-specific kinase (MuSK) and farnesyl-
transferase/geranylgeranyltransferase type-1 subunit a (FNTA).
To provide insight into GFPT1 myopathology, the spectrum of
affected proteins was analysed for enriched gene ontology
terms using STRING (Fig. 8A), and a pathway analysis was
performed based on functions described in uniprot (16) and
‘Reactome’ (Supplementary Material, Resource S13). We have
also verified the proteomic findings for glypican-1 and identified
increased protein abundance of MuSK in the muscles derived
from Gfpt1 mutant animals using immunoblot studies (Fig. 8B–D).
Discussion
Owing to the ubiquitous nature of GFPT1 and its expression in
the early stages of embryonic development, we confirmed that
complete knockout of this protein results in embryonic lethality
as homozygous GFPT1 knockout mice were never obtained
through breeding heterozygous knockout mice. In this study,
Figure 4. Fibre type labelling in control and Gfpt1tmld/tmld mouse muscle. Soleus (A) and TA (C) muscles were labelled with antibodies against MHC: Type 1 (blue) I, Type
IIa (red), Type IIb (green) and laminin (green). Type IIx fibres were labelled on a second section (not shown). There were no differences in the fibre type proportion in
both the soleus (n¼4) (B) and TA muscles (n¼4) (D).
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we report the generation of a Cre/loxP-mediated conditional
GFPT1 knockout mouse model and characterize the adult phe-
notype resulting from a deficiency of GFPT1 in skeletal muscle
only. Prior to this study it was unknown whether depletion of
GFPT1 in muscle only would be sufficient to produce a CMS-like
phenotype. Most pathogenic variants identified in patients with
GFPT1-CMS affect both GFPT1 isoforms resulting in reduced ex-
pression of the GFPT1 protein (10). To date, there has only been
one report of a patient harbouring a nonsense mutation in the
ubiquitous GFPT1 isoform and a second splice-site mutation
causing a frameshift at the muscle-specific GFPT1 exon, leading
to a complete loss of the muscle-specific isoform only (2).
The strategy used to generate the mouse model described in
this study was designed to disrupt both GFPT1 isoforms in
muscle only. Full realization of our model relies on our under-
standing of a temporally regulated series of events occurring in
skeletal muscle of the developing mouse embryo. Formation of
the NMJ begins with pre-patterning of AChRs from embryonic
day 12.5, and by embryonic day 18.5 AChR clusters have differ-
entiated and are well innervated (17,18). The expression of mus-
cle creatine kinase has been reported in skeletal and cardiac
muscle of the mouse embryo 13 days post coitum, which rapidly
increases by embryonic day 15 (19). The expression of Ckm-Cre,
and hence the depletion of GFPT1 temporally correlates with
events taking place during the formation of the NMJ.
Consequently, any phenotypes we observe in the GFPT1 mouse
model reflects the pathophysiology of the formation as well as
the maintenance of the NMJ, likely to occur owing to misglyco-
sylation of multiple proteins downstream of GFPT1.
Having established a muscle-specific GFPT1 deficient mouse
model, we investigated muscle strength and fatigue, and the
molecular biochemical effects of GFPT1 deficiency. Gfpt1tm1d/tm1d
mice are not readily distinguishable from control mice with re-
gard to physical appearance, general behaviour and motility,
but show a pronounced deficit in muscle strength and a greater
susceptibility to fatigue, similar to other mouse models of con-
genital myasthenia (20–22) and characteristic of human CMS
(4,7–9). Whilst patients often present with symptoms at later
stages of the disease, Gfpt1tm1d/tm1d mice present with muscle
weakness as early as 6 weeks old. This deficit in mutant mice
does not appear to be progressive over the first 6 months, but
may progress over longer periods of time. Fatigue induced in
Figure 5. Aberrant NMJs in 3 months old Gfpt1tm1d/tm1d mice. (A) Whole-mount TA, intercostal, soleus and EDL muscles were labelled with anti-neurofilament, anti-syn-
aptophysin and Alexa fluor 594 a-bungarotoxin. (B) Whole-mount TA muscles labelled with anti-synaptophysin and Alexa fluor 594 a-bungarotoxin demonstrating the
degree of co-localization of pre- and postsynaptic components. Quantitative analysis demonstrating AChR cluster area (C), and mean number of fragments/AChR clus-
ter (D) in control and Gfpt1tm1d/tm1d mice (n¼ 6). AChR fragments (blue arrows), discontinuous and disorganized axons (white arrow), presynaptic and postsynaptic over-
lap (magenta arrows). Data are mean6SEM. *P<0.05, **P<0.01, ***P<0.001; ns, not significant.
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the TA muscle following a high number of stimulations together
with a pronounced deficit in force produced by the diaphragm
muscle from Gfpt1tm1d/tm1d mice, is indicative of a myopathy,
and consistent with EMG recordings in patients with mutations
in GFPT1 as well as other genes in the glycosylation pathway in-
cluding ALG2, ALG14, DPAGT1 and GMPPB (1,2,4–9,12,23).
We also detected muscle fibre atrophy seen by a progressive
replacement of muscle tissue by fibroadipose tissue in the dia-
phragm muscle from 3 months old mice, which was absent in
younger (6 weeks old) mice (data not shown). These findings
correspond to the pathological changes observed in muscle
biopsies from DPAGT1-CMS patients (6). Whilst minor myo-
pathic changes are sometimes seen in some subtypes of CMS,
secondary to neurotransmission failure (24,25), more recently,
patient muscle MRI studies revealed pronounced myopathic
changes in patients with mutations in GFPT1 and DPAGT1, with
dystrophic changes reflected by fatty infiltration of the muscle
in patients with GMPPB mutations (26).
Gfpt1tm1d/tm1d mice demonstrate changes in endplate archi-
tecture illustrated by the fragmentation and reduction in size of
AChR clusters in all muscles examined, highlighting the impor-
tance of GFPT1 in NMJ differentiation. These pathological
changes are observed in a range of muscles regardless of fibre
type composition. The explicit morphological changes suggest a
synaptopathy that is likely to contribute to the muscle weak-
ness observed in Gfpt1tm1d/tm1d mice and may become more
obvious with disease progression. Notably, fragmentation and
smaller endplates are not necessarily indicators of impaired
neurotransmission as seen by recent investigations demon-
strating that neurotransmission remains unaffected in age-
related fragmentation of AChR clusters (27). To investigate the
underlying mechanisms that contribute to the observed
morphological alterations and subsequently the pathological
phenotype observed in Gfpt1tm1d/tm1d mice, we examined the sta-
bility of AChRs. Under normal conditions, AChRs cluster and
stabilize on the muscle membrane. Thereafter they are endocy-
tosed, recycled back to the membrane or are degraded (28).
Here, we examined whether deficiency of GFPT1 in the
Gfpt1tm1d/tm1d mouse muscle compromises the AChR turnover
rate. Whilst there were no significant changes in AChR turnover
rate between control and mutant mice, the presence of smaller
and fragmented AChRs suggests that trafficking of AChRs to
and from the endplate demonstrates some degree of impair-
ment, which is likely to be more prominent if the muscle is ex-
posed to stress.
Additional investigations revealed pathological changes in
intercostal muscle NMJs at the ultrastructural level. We ob-
served fewer and simplified junctional folds, a common feature
in GFPT1 patients (2,12) and other mouse models of congenital
myasthenia (20–22). Since a high density of Naþ channels are
found in the troughs of the junctional folds, it is possible that
simplification of the junctional folds may impair membrane de-
polarization and thus raise the threshold for muscle
action potential generation. Additional pathological changes
Figure 6. Altered morphology at the ultrastructural level in Gfpt1tm1d/tm1d mouse muscle. Representative electron micrographs from 3 months old control and
Gfpt1tm1d/tm1d intercostal muscles. Examples of control (A), and Gfpt1tm1d/tm1d (B–D) NMJs. Tubular aggregates (E) and subsarcolemmal vesicular structures (F–H) in
Gfpt1tm1d/tm1d mouse muscle. Synaptic vesicles (*), junctional folds (red arrow), mitochondria (M), tubular aggregates (TA), subsarcolemmal vesicular structures (white
arrow), dense filamentous-like material (blue arrowhead) (n¼4).
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we observe in Gfpt1tm1d/tm1d muscle include abnormal variations
in fibre size, few regenerating and necrotic fibres, and the pres-
ence of tubular aggregates. Our model closely resembles the
myopathic phenotype that we see in a patient harbouring the
c.686–2A>G mutation which disrupts the longer muscle-specific
isoform of GFPT1 resulting in the absence of glycosylated pro-
tein expression (2). Subsarcolemmal tubular aggregates are clas-
sified as densely packed vesicular or tubular membranes
derived from the sarcoplasmic reticulum (29). Not only are they
present in muscle biopsies from patients with mutations in pro-
teins involved in the glycosylation pathway (1–3,5,8,9) but are
also implicated in myopathies resulting from STIM1 and ORAI1
mutations (30–32), and are present in muscle from Caveolin1/
and Caveolin2/ mice (29). Whether tubular aggregates are direct
pathological components contributing to the observed pheno-
type, or whether they represent a compensatory mechanism to
pathological events, or a bystander event that is not connected to
the functional impairment is poorly understood, making it chal-
lenging to understand the molecular mechanisms that induce
tubular aggregates (33). In the context of defective glycosylation
induced-CMS, one hypothesis is that the tubular aggregates
originate from an accumulation of defective proteins consequent
to impaired glycosylation. Although we observe a mild predomi-
nance of tubular aggregates in Type 2 fibres from Gfpt1tm1d/tm1d
soleus muscles, this observation may become more robust with
disease progression. Interestingly, we also discovered the pres-
ence of moderately proliferated sarcoplasmic reticulum and
Golgi structures in Gfpt1tm1d/tm1d mouse intercostal muscles.
Owing to the subcellular localization of GFPT1 and its role in
post-translational protein modifications that take place within
these two compartments under normal conditions, aberrant pro-
tein accumulation may arise in the cytoplasm of GFPT1 deficient
mouse muscle. Similar ectopic proteins suggesting an ER-Golgi-
stress response are also observed in caveolin-3-related muscle
diseases (34), (G. Coraspe, manuscript in preparation).
The presynaptic alterations we observe include disorganized
axons, thinner irregular myelin sheaths and remodelling of mo-
tor nerve terminals. Since our model conserves GFPT1 expres-
sion in non-muscle tissues, we speculate that the presynaptic
changes we observe in Gfpt1tm1d/tm1d NMJs are secondary to the
pathological changes in the postsynaptic apparatus. Previous
studies have reported presynaptic alterations owing to a
Figure 7. Caveolin-3 expression in muscles from control (n¼3) and Gfpt1tm1d/tm1d (n¼4) mice. Transverse sections of the soleus (A) and TA muscles were labelled with
an antibody against caveolin-3. No significant differences in the percentage of myofibres expressing caveolin-3 were observed in the soleus (B) and TA (C) muscles
from Gfpt1tm1d/tm1d mice compared with controls. Caveolin-3 positive punctate were significantly larger in Gfpt1tm1d/tm1d soleus (D) and TA (E) muscles compared with
controls. Data are mean6SEM. **P<0.01, ****P< 0.0001.
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deficiency of muscle derived NMJ proteins. The inducible LRP4
muscle-specific knockout mouse model displays postsynaptic
remodelling that is accompanied by presynaptic changes
(35,36). Similarly, the muscle-specific conditional b-catenin
knockout mouse model demonstrates morphological and func-
tional defects in NMJ nerve terminals, yet there are no presyn-
aptic pathological changes in the motor neuron-specific b-
catenin knockout mouse model (37). It is possible that the pre-
synaptic changes we observe in Gfpt1tm1d/tm1d mice occur owing
to defective muscle derived proteins, which could be GFPT1 it-
self, or misglycosylation of binding partners and activators re-
quired for neuronal differentiation and maintaining the
integrity of myelin sheaths.
Since glycosylation is a ubiquitous post-translational modifi-
cation, it is highly probable that GFPT1 is responsible for the gly-
cosylation of proteins other than those required for the
formation and maintenance of the NMJ complex. Proteomic pro-
filing of GFPT1 deficient intercostal muscles revealed altered
abundance of 2.8% of the quantified proteins affecting different
pathways/cellular functions including the ER/SR-Golgi function
and protein glycosylation. Here, we identified an upregulation
of O-GlcNAc transferase (OGT), which is responsible for catalys-
ing the addition of a single GlcNAc to a serine or threonine resi-
due in the O-GlcNAcylation pathway (38), and is regulated by
the cellular levels of UDP and UDP-GlcNAc. Previous observa-
tions of a distinct decrease of O-GlcNAc proteins are also seen
in human GFPT1-deficiency (10). It is likely that the increased
expression of OGT in GFPT1 deficient muscle serves as a com-
pensatory mechanism owing to a lack of the precursor donor
UDP-GlcNAc. Moreover, our proteomics analyses revealed an
increase of glypican-1, a heparan sulphate proteoglycan pre-
dominantly expressed in neural tissues and skeletal
muscle, and is important for modulating growth factors and
influencing axon guidance, Schwann cell myelination and skel-
etal muscle differentiation (39–41). The increase in glypican-1 in
Gfpt1tm1d/tm1d mouse muscle may serve as a mechanism for
skeletal muscle to counter high stress levels, as glypican-1 was
previously shown to be upregulated after severe denervation in
skeletal muscles as an anti-fibrotic response (42). Interestingly,
glypican-1 co-localizes with caveolin-positive endosomal struc-
tures displaying a pronounced association upon the initiation of
ER-Golgi-stress (43). Notably, via electron microscopic studies,
we identified an increase of subsarcolemmal vesicular struc-
tures in Gfpt1tm1d/tm1d mouse muscle that may correspond to
caveolae that have not fused with the sarcolemma. This
prompted the investigation of the abundance and distribution
of subcellular caveolin-3 in GFPT1-deficient muscle showing
that the size of the sarcoplasmic puncta immunoreactive for
caveolin-3 are significantly larger in mutant muscles compared
with controls. As caveolins are required for caveolae-formation
(44,45), the larger sarcoplasmic caveolin-3 deposits may influ-
ence proper formation of caveolae. Furthermore, tubular aggre-
gates are also present in muscle from Caveolin1/ and
Caveolin2/ mice (29), suggesting that caveolin proteins may
play a role in preventing the formation of tubular aggregates.
We also see an increase of FNTA, an essential subunit of the
geranylgeranyltransferase complex that is implicated in syn-
apse formation by playing an active role in the agrin/MuSK
pathway (46). Notably, we see an increase in the expression of
MuSK, a protein essential for AChR clustering (21,22,47). The ab-
normal proteomic profile of GFPT1-deficient mouse muscle
allows first insights into dysregulated molecular pathways, but
further work is required to elucidate the cellular and subcellular
origin of the dysregulated proteins and to elucidate the underly-
ing pathomechanism downstream of GFPT1. Our unbiased
proteomic study is limited, as membrane-bound and low-
abundant proteins such as the subunits of the AChR may be
underrepresented or undetectable. Additional experiments, e.g.
glycoproteomics on sub-fractions of enriched membranes may
Figure 8. Proteins regulated as a consequence of GFPT1 depletion in 3 months old intercostal muscles. (A) STRING analyses demonstrating the spectrum of affected
proteins. Proteins that show upregulation (green) and downregulation (red) are shown. (B) Immunoblot studies show upregulation of glypican-1 and MuSK proteins in
Gfpt1tm1d/tm1d mice. Quantitative analysis showing the relative expression levels of glypican-1 (C) (n¼3), and MuSK (D) (n¼2) normalized to their corresponding a-acti-
nin loading controls.
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be required to refine the putative glycosylation targets affected
by GFPT1 deficiency.
In conclusion, we report a novel GFPT1 deficient mouse
model that closely resembles the human GFPT1-CMS phenotype
on a histological and functional level. Our model provides new
insights into proteins that are regulated owing to a complete
loss of GFPT1 in muscle, highlights the importance of protein
glycosylation in maintaining the integrity of the NMJ and mus-
cle, and provides an enhanced understanding of the pathologi-
cal and possible compensatory mechanisms occurring in the
absence of GFPT1. Importantly, we identify a myopathic pheno-
type in the Gfpt1tm1d/tm1d mouse model corresponding to that
seen in patients with CMS who harbour mutations in proteins
involved in the N-glycosylation pathway. Whilst current thera-
pies symptomatically target the myasthenic phenotype, it is un-
likely that the myopathy can be reversed. Since GFPT1 is the
rate limiting enzyme in the N- and O-glycosylation pathways, it
is plausible that the discoveries made from this model may also
be true for other glycosylation defective CMS.
Materials and Methods
Mice
All procedures were approved by the Home Office and were car-
ried out in accordance to the Animals Scientific Procedures Act
of 1986 under project licence 70/8538. AChR turnover experi-
ments were approved by German authorities and were con-
ducted in accordance with national law (TierSchG7). Mice used
for this study were bred in the animal facility at the Functional
Genomics Unit, Institute of Genetic Medicine, Newcastle
University. Breeders were housed as pairs of one male and one
female, or trios of one male and two females. Offspring were
housed together in groups of 2–6. Gfpt1tm1a (EUCOMM)Wtsi and
[B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J] strains were obtained
from The Jackson Laboratory. Gfpt1tm1c(EUCOMM)Wtsi and Gfpt1tm1d
(EUCOMM)Wtsi strains were generated in-house.
Generation of Gfpt1tm1d/tm1d mutant mice and
genotyping
All mice used in this study were bred on a C57BL/6N back-
ground. The Gfpt1tm1c allele harbouring a floxed lacZ-neomycin
trapping cassette was established as part of the International
Mouse Phenotyping Consortium, MRC Harwell. This line was
crossed with a Cre deleter mouse whereby the Cre transgene is
driven by the muscle creatine kinase (Ckm) promoter, resulting
in excision of the floxed exon. The following primers were used
for PCR verification of tissue specific Cre-mediated recombina-
tion: Control PCR, (F1) 50 CATGCGTGAACCTGTGTACA 30 and (R1)
50 GTCAGAGTTTGCTCACATCA 30. Mutant PCR, (F1) 50 CATGC
GTGAACCTGTGTACA 30 and (R2) 50 GGGTTTCGTAATTGGA
AGAG 30. Control tissues amplified sequences of 500 bp, and
the mutant amplification was 290 bp long. The presence of Cre
was detected using the following primers: (CreF) 50 TAAGT
CTGAACCCGGTCTGC 30 and (CreR) 50 GTGAAACAGCATTGCTGT
CACTT 30, producing a sequence of 450 bp. Male mice were
used for all experiments in this study.
Inverted screen measurement
Animals were suspended from an inverted wire grid and the la-
tency to release their grip was recorded. Mice were permitted to
hold on for a maximum time of 10 min. Mice that released their
grasp before reaching 10 min were given a rest period of 5 min
and were given up to two more tries. The maximum hang time
was used for further analysis. Data were collected from mice as
early as 6 weeks old and animals were tested once a week over
a period of 6 months.
Ex vivo isometric tension analysis
Three months old mice were sacrificed via cervical dislocation
and a strip of diaphragm muscle from the central tendon to the
ribs was excised immediately and assembled in a tissue organ
bath (Aurora Scientific) filled with oxygenated Krebs-Ringer so-
lution (154 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
11 mM glucose and 5 mM HEPES) at pH 7.4, maintained at 22C.
One end of the diaphragm was attached to a 300C dual-mode
servomotor transducer (Aurora Scientific) and the central ten-
don secured to a rigid post using 4-0 surgical thread. Diaphragm
muscles were stimulated by supramaximal 0.2 ms square wave
pulses delivered to the nerve via platinum electrodes positioned
on either side of the muscle. Data acquisition and control of the
servomotor was conducted using a LabView-based DMC pro-
gram (Dynamic muscle control and Data Acquisition; Aurora
Scientific, Version 3.2). We established a forcefrequency rela-
tionship and assessed muscle resistance to fatigue. The
muscle’s optimum length (Lo) was determined using single
0.5 ms isometric twitch stimulations. The maximum isometric
tetanic force was established by stimulating the muscle with
0.5 ms pulses at Lo for a period of 500 ms at 150 Hz. The fatigue
protocol involved 100 isometric contractions at a frequency of
150 Hz. This procedure was carried out in accordance with
TREAT-NMD protocols.
In situ force measurement
Mice were anaesthetized with an intraperitoneal injection of
HypnormVR /HypnovelVR /water (1:1:2) at a dosage of 6 ml/g.
Anaesthesia was maintained by mask inhalation of isoflurane
vaporized at concentrations of up to 4% during surgical proce-
dures and at 0.8–1.3% throughout the rest of the procedure.
The distal tendon of the TA muscle was exposed and freed from
surrounding fascia and tied with 4-0 surgical braided silk. The
sciatic nerve was exposed and all branches were severed except
for the common peroneal nerve (CPN) that innervates the TA.
The mouse was placed on a heated stage (Aurora Scientific) to
maintain body temperature at 37C. The TA tendon was at-
tached to the lever arm of a 300C dual-mode servomotor trans-
ducer (Aurora Scientific). Contractions of the TA muscle were
simulated via supramaximal square-wave pulses of 0.2 ms
(701B Stimulator; Aurora Scientific) to the distal part of the CPN
via bipolar platinum electrodes. Data acquisition and control of
the servomotor was conducted using a LabView-based DMC
program (Dynamic muscle control and Data Acquisition; Aurora
Scientific, Version 3.2).
Muscles were stimulated using a warm up protocol that con-
sisted of 5 stimulations at 50 Hz with a minute rest period be-
tween each stimulation. The muscle was subject to a series of
single twitches at increasing tensions. The muscle’s optimum
length (Lo) was determined and the resting tension that pro-
duced the strongest twitch was used throughout the experi-
ment. The force frequency relationship was determined using a
series of stimulations at 10, 30, 40, 50, 80, 100, 120, 150
and 180 Hz, each 1 min apart. A stimulation frequency of 120 Hz
produced a fully fused tetanus with no reduction in force over
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the stimulation period. This is the maximum isometric tetanic
force (Po).
The force readings at each frequency recorded in grams (ab-
solute force) were converted to specific force (kN/m2). Specific
force is the absolute force normalized to CSA of the muscle. The
following formula was used to determine the CSA of the muscle:
CSA ¼muscle weight (g)/[optimum TA fibre length (Lf, cm) 1.06
(g/cm3)]. Specific force (N/cm2) was calculated using the follow-
ing formula: specific force (N/cm2) ¼Absolute force (N)/CSA
(cm2); 1.06 g/cm3 is the density of mammalian skeletal muscle.
Lf ¼optimal length (Lo) 0.6 that represents the fibre length:
muscle length ratio for the TA (48).
We also established the force–frequency relationship and
assessed the susceptibility of the TA muscle to fatigue. The fa-
tigue protocol involved stimulating the muscle every 2 s at
120 Hz (Po) 100 times. Force produced upon muscle contraction
was recorded after every 10 stimulations. These data are
expressed as a percentage of baseline values (force produced
after every 10 stimulations). At the end of the experiment,
mice were sacrificed via cervical dislocation and muscles were
excised and weighed.
Antibodies
The following antibodies were used in this study.
Whole-mount muscle staining: mouse monoclonal anti-
neurofilament (1:200, Abcam), rabbit polyclonal anti-synaptophysin
(1:100, Thermo Fisher Scientific), Alexa FluorVR 594 a-bungarotoxin
conjugate (1:500, Thermo Fisher Scientific), Alexa FluorVR 488 goat
anti-mouse (1:500, Thermo Fisher Scientific), Alexa FluorVR 488 goat
anti-rabbit (1:500, Life Technologies); western blotting: rabbit poly-
clonal anti-GFPT1 (1:500, Proteintech), mouse monoclonal anti-
GAPDH (1:1000, Abcam), rabbit polyclonal anti-glypican 1 (1:1000,
Abcam), rabbit polyclonal anti-MuSK (1:1000, Abcam), mouse
monoclonal anti-a actinin (1:250, Sigma). Secondary antibodies:
IRDyeVR 800CW Donkey anti-Mouse IgG, IRDyeVR 680CW goat anti-
rabbit IgG; AChR turnover experiments: Alexa FluorVR 647 a-bungaro-
toxin conjugate (25 pmol, Thermo Fisher Scientific) and Alexa
FluorVR 488 a-bungarotoxin conjugate (25 pmol, Thermo Fisher
Scientific); Caveolin-3 labelling: rabbit polyclonal anti-caveolin-3
(1:100, Abcam). Secondary antibodies: Alexa FluorVR 594 goat anti-
rabbit (1:100, Thermo Fisher Scientific); Fibre type identification: rabbit
polyclonal IgG anti-laminin (Sigma 1:750), MHCI (BA-F8 Mouse
monoclonal IgG2b) 1:25, MHCIIa (Sc71, Mouse monoclonal IgG1)
1:200, MHCIIx (6H1 Mouse monoclonal IgM) 1:25 and MHCIIb (BF-F3
Mouse monoclonal IgM) 1:200 all from Developmental Studies
Hybridoma Bank. Secondary antibodies: Alexa FluorVR 488 IgG goat
anti-rabbit (1:500, Thermo Fisher Scientific), Alexa FluorVR 350 IgG2b
goat anti-mouse (1:500, Thermo Fisher Scientific), Alexa FluorVR 594
IgG1 goat anti-mouse (1:100, Thermo Fisher Scientific) and Alexa
FluorVR 488 IgM goat anti-mouse (1:500, Thermo Fisher Scientific).
Immunohistochemistry
Histology of muscle
Transverse 10 mm sections of TA, intercostal, soleus and EDL
muscles were cut using a cryostat (Microm HM 560, Zeiss).
Sections were stained with haematoxylin and eosin according
to standard procedures. Slides were mounted with DPX
Mounting Medium (LAMB) and images were acquired using a
Zeiss Axioplan microscope and AxioVision software.
Fibre type identification
Transverse 10 mm sections of soleus and TA muscles were cut us-
ing a cryostat (Microm HM 560, Zeis) and labelled for Myosin
Heavy Chains (MHC) MHCI, MHCIIa, and MHCIIb and MHCIIx (49).
Sections were blocked (10% normal goat serum in PBS) for 1 h at
room temperature and then incubated with the following
primary antibodies: anti-laminin, anti-MHCI, anti-MHCIIa, anti-
MHCIIx and anti-MHCIIb for 1 h at room temperature. Sections
were washed in PBS and incubated in secondary antibodies for
1 h. Sections were then washed and mounted using Vectashield
hardset mounting medium (Vector Laboratories). Tiled images of
the whole sections were captured using a Zeiss Axio Imager fluo-
rescent microscope with Zen software and analysed using
ImageJ analysis software.
Whole-mount muscle staining
Whole muscles were dissected and fixed (1% paraformaldehyde
in 0.1 M phosphate buffer) for 30 min. They were then incubated
with Alexa FluorVR 594 a-bungarotoxin conjugate in Liley’s solu-
tion (12 mM NaHCO3, 4 mM KCl, 1 mM KH2PO4, 138.8 mM NaCl,
1 mM MgCl2, 2 mM CaCl2, 11 mM glucose; Sigma-Aldrich) for 1 h.
Muscle fibres were teased into small bundles during washes.
Muscles were permeabilized in ethanol followed by methanol
(10 min at 20C), followed by an incubation in 0.1% Triton
X-100 in PBS (for 15 min, room temperature). Muscles were incu-
bated overnight with antibodies against neurofilament and syn-
aptophysin in PBS containing 3% BSA (Sigma-Aldrich) and 0.1 M
lysine (Sigma-Aldrich). The next day muscles were incubated in
Alexa FluorVR 488 secondary antibodies for 3 h at room tempera-
ture and washed in PBS overnight. The muscles were mounted
on slides with Vectashield mounting medium with DAPI (Vector
Laboratories). Samples were visualized using a Nikon A1R laser
scanning confocal microscope. Laser power and parameter set-
tings were kept constant and Z-stack images were acquired and
processed using NIS-elements AR 4.20.02 software. For quantifi-
cation of the AChR cluster area, single-projected images derived
from overlaying image stacks were analysed by ImageJ analysis
software using a thresholding approach.
Caveolin-3 labelling
Cryosections from the soleus and TA muscles were taken at
10 lm using a CM1860 cryostat (Leica) and mounted on
Histobond adhesion microscope slides. Sections were permeabi-
lized (0.5% Triton X-100 in TBS) for 10 min and blocked (10% nor-
mal goat serum in TBS) for 30 min at room temperature, and
then incubated with an antibody against caveolin-3 for 2 h at
room temperature. Sections were washed and incubated in sec-
ondary antibodies for 1 h at room temperature. Sections were
then washed and mounted using Vectashield hardset mounting
medium (Vector Laboratories). Tiled images were acquired using
a Zeiss Axioplan microscope and camera. Analysis was per-
formed using ImageJ and GraphPad Prism v7. The number of
fibres expressing caveolin-3 was counted and determined rela-
tive to the total number of fibres present. The size of caveolin-3
punctate was determined using a thresholding approach.
Transmission electron microscopy
Fresh tissue samples of intercostal muscles were fixed in 3.9%
buffered glutaraldehyde, osmicated in 1% phosphate-buffered
osmium tetroxide, dehydrated and embedded in epoxy resin.
One micrometre of semi-thin sections was stained with toluidine
blue. Ultrathin sections (100 nm) of at least one transverse and
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one longitudinal block per animal were contrasted by uranyl ace-
tate and lead citrate as previously described (50). Electron micros-
copy images were recorded using a CM10 transmission electron
microscopy (Philips, Amsterdam, the Netherlands).
In vivo visualization and measurement of AChR
turnover rate
Mice were anaesthetized under isoflurane vaporized at concen-
trations of 0.6–1.5%, and administered an intramuscular injec-
tion of 25 pmol of a-bungarotoxin 488 (green) in the TA muscle.
Ten days later, mice were administered a combination of
Xylazin (Bayer) and Zoletil (Laboratories Virba) by intraperito-
neal injection, and administered an intramuscular injection of
25 pmol a-bungarotoxin 647 (red). One hour following the sec-
ond administration, superficial TA muscles were examined us-
ing microscopy. Briefly, 3D stacks at 512 512 pixel resolution
were taken of a-bungarotoxin 488 signals (old receptors) and of
a-bungarotoxin 647 signals (new receptors) using a 63 objec-
tive and confocal in vivo imaging. The 3D stacks were automati-
cally segmented using a custom-made algorithm and pixel
signal intensity values for each channel were extracted. The
fraction of pixels per NMJ was calculated.
Western blots
Tissues were homogenized in lysis buffer (RIPA buffer,
ThermoScientific) and protease inhibitors (Complete EDTA-free
protease inhibitor, Roche) using a tissue raptor (Qiagen).
Samples were centrifuged and the protein-containing superna-
tant was collected for immunoblot analyses. Proteins were re-
solved by SDS-PAGE on Novex NuPAGE 4–12% Bis–Tris Gels
(Thermo Fisher Scientific) for 45 min at 200 V, and transferred
onto PVDF membranes (Licor). Membranes were blocked with
TBS blocking buffer (Licor) and incubated with primary antibod-
ies in blocking solution containing 0.2% Tween-20, overnight at
4C. After washing with TBS/Tween-20, membranes were incu-
bated with IRDyeVR 800CW Donkey anti-Mouse IgG, IRDyeVR
680CW Goat anti-Rabbit IgG secondary antibodies diluted in TBS
blocking buffer containing 0.2% Tween-20 and 0.01% SDS for
1 h. Membranes were washed with TBS/Tween-20 and TBS, and
immunoreactive proteins were detected using an Odyssey infra-
red scanner (Licor Biosciences).
Proteomic profiling of GFPT1 deficient intercostal
muscles
Proteomic profiling was conducted using a label-free LC-MS/MS.
Materials and methods are described in Supplementary
Material, Resource S14.
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics
22.0 software. Data were analysed using a two-sample t-test
when variances did not differ between samples. An indepen-
dent sample Mann–Whitney U test was performed to compare
myofibre size variation as the data did not follow a normal dis-
tribution. Proteomic data were analysed as described in
Supplementary Material, Resource S1. P< 0.05 was considered
statistically significant.
Supplementary Material
Supplementary Material is available at HMG online.
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